IP Library Granted Patent US 12,018,297
Granted Patent B2
US 12,018,297 · App. 17/258,776 · Granted Jun 25, 2024

Nuclease-mediated nucleic acid modification

Inventors: Jie Xu (Troy, MI); Jifeng Zhang (Ann Arbor, MI); Yuqing Eugene Chen (Superior Township, MI); Dongshan Yang (Ann Arbor, MI)
Assignee: The Regents of The University of Michigan
C12N9/22A01K67/0275C12N15/102C12N15/111C12N15/8509A01K2207/05A01K2217/072C07K2319/81C12N2310/20
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,018,297
App. No.
17/258,776
Granted
Jun 25, 2024
Kind
B2
Abstract

Provided herein is technology relating to molecular biological manipulation of genes and genomes and particularly, but not exclusively, to CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) methods, compositions, systems, and kits for improved genetic editing.

Claims (15)

1. A gene editing fusion protein comprising a gene editing nuclease domain fused to a plurality of at least two BE27 domains, wherein the gene editing nuclease domain comprises a CRISPR-associated system (Cas) protein domain and each BE27 domain of said plurality of BE27 domains comprises a polypeptide having the amino acid sequence of SEQ ID NO: 1.

2. The gene editing fusion protein of claim 1 wherein said Cas protein domain is from a Cas protein selected from the group consisting of Cas1, Cas1B, Cas2, Cas3, Cas4, Cas5, Cas6, Cas7, Cas8, Cas9, Cas10, Cas13, Csy1, Csy2, Csy3, Cse1, Cse2, Csc1, Csc2, Csa5, Csn2, Csm2, Csm3, Csm4, Csm5, Csm6, Cmr1, Cmr3, Cmr4, Cmr5, Cmr6, Csb1, Csb2, Csb3, Csx17, Csx14, Csx10, Csx16, CsaX, Csx3, Csx1, Csx15, Csf1, Csf2, Csf3, Csf4, Cpf1, C2c1, C2c2, HiFiCas9, spCas9mSA, HypaCas9, and xCas9.

3. The gene editing fusion protein of claim 1 , wherein said plurality of BE27 domain comprises a tandem array of BE27 domains.

4. The gene editing fusion protein of claim 1 , wherein said plurality of BE27 domains comprises one or more linker sequences separating the BE27 domain.

5. The gene editing fusion protein of claim 1 , wherein said plurality of BE27 domains comprises 2-10 BE27 domains.

6. A composition comprising the gene editing fusion protein of claim 1 .

7. The composition of claim 6 , further comprising a gRNA.

8. The composition of claim 6 , further comprising a donor nucleic acid.

9. The composition of claim 6 , further comprising a target nucleic acid.

10. The composition of claim 8 , wherein said donor nucleic acid comprises 100 to 1000 bp.

11. The composition of claim 8 , wherein said donor nucleic acid comprises 1000 to 10,000 bp.

12. The composition of claim 6 , further comprising a RAD51 protein or a nucleic acid encoding a RAD51 protein.

13. The composition of claim 6 , further comprising a plurality of RAD51 proteins.

14. The composition of claim 6 , further comprising a nucleic acid comprising a knockin.

15. The composition of claim 14 , wherein said nucleic acid comprising a knockin comprises a sequence of a donor nucleic acid.

Assignments (2)
CONFIRMATORY LICENSE Recorded Jan 19, 2024
From: UNIVERSITY OF MICHIGAN
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 066356/0247 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 17, 2021
From: XU, JIE; ZHANG, JIFENG; CHEN, YUQING EUGENE; YANG, DONGSHAN
To: THE REGENTS OF THE UNIVERSITY OF MICHIGAN
Reel/Frame 057513/0015 →
Continuity (2)
Provisional Application 62698376 · Jul 16, 2018
Related Publication 20210301272A1 · Sep 30, 2021